EGFR and non-small cell lung carcinoma: Future research using EGFR-dependent models will be necessary to fully confirm the clinical relevance of this combination, especially for EGFR-mutant NSCLC, and to determine the precise contribution of EGFR inhibition to the observed synergistic effect.